|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gansler T, Ganz PA, Grant M, Greene FL,
Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, et
al: Sixty years of CA: A cancer journal for clinicians. CA Cancer J
Clin. 60:345–350. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeSantis CE, Fedewa SA, Goding Sauer A,
Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015:
Convergence of incidence rates between black and white women. CA
Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He M, Guo Q and Hu G: Reversed urban-rural
differences in breast cancer mortality (China, 2002–2008). Breast
Cancer Res Treat. 126:231–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mahamodhossen YA, Liu W and Rong-Rong Z:
Triple-negative breast cancer: New perspectives for novel
therapies. Med Oncol. 30:6532013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bilal E, Dutkowski J, Guinney J, Jang IS,
Logsdon BA, Pandey G, Sauerwine BA, Shimoni Y, Moen Vollan HK,
Mecham BH, et al: Improving breast cancer survival analysis through
competition-based multidimensional modeling. PLoS Comput Biol.
9:e10030472013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Freedman GM and Fowble BL: Local
recurrence after mastectomy or breast-conserving surgery and
radiation. Oncology (Williston Park). 14:1561–1581. 2000.PubMed/NCBI
|
|
8
|
Duffy MJ: Biochemical markers in breast
cancer: Which ones are clinically useful? Clin Biochem. 34:347–352.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mohammadzadeh F, Mosayebi G, Montazeri V
and Darabi M, Fayezi S, Shaaker M, Rahmati M, Baradaran B,
Mehdizadeh A and Darabi M: Fatty acid composition of tissue
cultured breast carcinoma and the effect of stearoyl-coa desaturase
1 inhibition. J Breast Cancer. 17:136–142. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo Y, Wang P, Li X, Zhu S, Xu H, Li S,
Deng H and Yuan L: Identifying a BRCA2 c.5722_5723del mutation in a
Han-Chinese family with breast cancer. Biosci Rep. 39:2019.
View Article : Google Scholar
|
|
11
|
Rawlings ND, Barrett AJ and Bateman A:
MEROPS: The database of proteolytic enzymes, their substrates and
inhibitors. Nucleic Acids Res. 40:D343–D350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kabel AM: Tumor markers of breast cancer:
New prospectives. J Oncol Sci. 3:5–11. 2017.
|
|
13
|
Tan G, Liu Q, Tang X, Kang T, Li Y, Lu J,
Zhao X and Tang F: Diagnostic values of serum cathepsin B and D in
patients with nasopharyngeal carcinoma. BMC Cancer. 16:2412016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uhlman A, Folkers K, Liston J, Pancholi H
and Hinton A: Effects of vacuolar H+-ATPase inhibition on
activation of cathepsin B and Cathepsin L secreted from MDA-MB231
breast cancer cells. Cancer Microenviron. 10:49–56. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sudhan DR, Rabaglino MB, Wood CE and
Siemann DW: Cathepsin L in tumor angiogenesis and its therapeutic
intervention by the small molecule inhibitor KGP94. Clin Exp
Metastasis. 33:461–473. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Li X, Peng D, Tan Z, Liu H, Qing Y,
Xue Y and Shi GP: Usefulness of serum Cathepsin L as an independent
biomarker in patients with coronary heart disease. Am J Cardiol.
103:476–481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sui H, Shi C, Yan Z and Wu M:
Overexpression of Cathepsin L is associated with chemoresistance
and invasion of epithelial ovarian cancer. Oncotarget.
7:45995–46001. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sudhan DR and Siemann DW: Cathepsin L
targeting in cancer treatment. Pharmacol Ther. 155:105–116. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
World Medical Association, . World Medical
Association declaration of helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Chen J, Zhong MZ, Huang J, Hu YP,
Feng DY, Zhou ZJ, Luo X, Liu ZQ, Jiang WZ and Zhou WB:
Overexpression of ANLN contributed to poor prognosis of
anthracycline-based chemotherapy in breast cancer patients. Cancer
Chemother Pharmacol. 79:535–543. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sorlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Prolc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar
|
|
24
|
Perou CM, Sorlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma XJ, Dahiya S, Richardson E, Erlander M
and Sgroi DC: Gene expression profiling of the tumor
microenvironment during breast cancer progression. Breast Cancer
Res. 11:R72009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao H, Langerod A, Ji Y, Nowels KW,
Nesland JM, Tibshirani R, Bukholm IK, Kåresen R, Botstein D,
Børresen-Dale AL and Jeffrey SS: Different gene expression patterns
in invasive lobular and ductal carcinomas of the breast. Mol Biol
Cell. 15:2523–2536. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Richardson AL, Wang ZC, De Nicolo A, Lu X,
Brown M, Miron A, Liao X, Iglehart JD, Livingston DM and Ganesan S:
X chromosomal abnormalities in basal-like human breast cancer.
Cancer Cell. 9:121–132. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weigman VJ, Chao HH, Shabalin AA, He X,
Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, et
al: Basal-like breast cancer DNA copy number losses identify genes
involved in genomic instability, response to therapy, and patient
survival. Breast Cancer Res Treat. 133:865–880. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mullins M, Perreard L, Quackenbush JF,
Gauthier N, Bayer S, Ellis M, Parker J, Perou CM, Szabo A and
Bernard PS: Agreement in breast cancer classification between
microarray and quantitative reverse transcription PCR from
fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clin
Chem. 53:1273–1279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chanrion M, Negre V, Fontaine H, Salvetat
N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F,
Theillet C and Darbon JM: A gene expression signature that can
predict the recurrence of tamoxifen-treated primary breast cancer.
Clin Cancer Res. 14:1744–1752. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goswami CP and Nakshatri H: PROGgeneV2:
Enhancements on the existing database. BMC Cancer. 14:9702014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou W, Guan X, Wang L, Liao Y and Huang
J: p12(CDK2-AP1) inhibits breast cancer cell proliferation and in
vivo tumor growth. J Cancer Res Clin Oncol. 138:2085–2093. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Herszenyi L, Barabas L, Hritz I, Istvan G
and Tulassay Z: Impact of proteolytic enzymes in colorectal cancer
development and progression. World J Gastroenterol. 20:13246–13257.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Herszenyi L, Lakatos G, Hritz I, Varga MZ,
Cierny G and Tulassay Z: The role of inflammation and proteinases
in tumor progression. Dig Dis. 30:249–254. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mason SD and Joyce JA: Proteolytic
networks in cancer. Trends Cell Biol. 21:228–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tan GJ, Peng ZK, Lu JP and Tang FQ:
Cathepsins mediate tumor metastasis. World J Biol Chem. 4:91–101.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Turk B: Targeting proteases: Successes,
failures and future prospects. Nat Rev Drug Discov. 5:785–799.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tholen M, Wolanski J, Stolze B, Chiabudini
M, Gajda M, Bronsert P, Stickeler E, Rospert S and Reinheckel T:
Stress-resistant translation of Cathepsin L mRNA in breast cancer
progression. J Biol Chem. 290:15758–15769. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sudhan DR, Pampo C, Rice L and Siemann DW:
Cathepsin L inactivation leads to multimodal inhibition of prostate
cancer cell dissemination in a preclinical bone metastasis model.
Int J Cancer. 138:2665–2677. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sigloch FC, Tholen M, Gomez-Auli A,
Biniossek ML, Reinheckel T and Schilling O: Proteomic analysis of
lung metastases in a murine breast cancer model reveals divergent
influence of CTSB and CTSL overexpression. J Cancer. 8:4065–4074.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cao Y, Liu X, Li Y, Lu Y, Zhong H, Jiang
W, Chen AF, Billiar TR, Yuan H and Cai J: Cathepsin L activity
correlates with proteinuria in chronic kidney disease in humans.
Int Urol Nephrol. 49:1409–1417. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fei Y, Xiong Y, Zhao Y, Wang W, Han M,
Wang L, Tan C and Liang Z: Cathepsin L knockdown enhances
curcumin-mediated inhibition of growth, migration, and invasion of
glioma cells. Brain Res. 1646:580–588. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han ML, Zhao YF, Tan CH, Xiong YJ, Wang
WJ, Wu F, Fei Y, Wang L and Liang ZQ: Cathepsin L
upregulation-induced EMT phenotype is associated with the
acquisition of cisplatin or paclitaxel resistance in A549 cells.
Acta Pharmacol Sin. 37:1606–1622. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qingqing Z, Meiling H, Wenjuan W, Song Y,
Chen G, Wang Z and Liang Z: Downregulation of Cathepsin L
suppresses cancer invasion and migration by inhibiting transforming
growth factor?β?mediated epithelial?mesenchymal transition. Oncol
Rep. 33:1851–1859. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Qin G, Cai Y, Long J, Zeng H, Xu W, Li Y,
Liu M, Zhang H, He ZL and Chen WG: Cathepsin L is involved in
proliferation and invasion of breast cancer cells. Neoplasma.
63:30–36. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
He X, Xiang H, Zong X, Yan X, Yu Y, Liu G,
Zou D and Yang H: CDK2-AP1 inhibits growth of breast cancer cells
by regulating cell cycle and increasing docetaxel sensitivity in
vivo and in vitro. Cancer Cell Int. 14:1302014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chai J, Ju J, Zhang SW, Shen ZY, Liang L,
Yang XM, Ma C, Ni QW and Sun MY: p12CDK2-AP1 interacts with CD82 to
regulate the proliferation and survival of human oral squamous cell
carcinoma cells. Oncol Rep. 36:737–744. 2016. View Article : Google Scholar : PubMed/NCBI
|
